Angiopoietin-1 gene therapy attenuates hypertension and target organ damage in nitric oxide synthase inhibited spontaneously hypertensive rats

Korean Circulation Journal

Volumn 41, Issue 10, 2011, Pages 590-595

  Suh, Wonhee ^a   Lee, Jung Sun ^b   Kim, Koung Li ^a,b   Song, Sun Hwa ^a   Koh, Gou Young ^c   Kim, Duk Kyung ^b  

^a Ajou University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Angiopoietin 1; Endothelium; Hypertension; Nitric oxide

Indexed keywords

ANGIOPOIETIN 1; CARTILAGE OLIGOMERIC MATRIX PROTEIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE THERAPY; GENE TRANSFER; HISTOLOGY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PLASMID; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 82055207333     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2011.41.10.590     Document Type: Article

References (19)

1. Cohuet G, Struijker-Boudier H. Mechanisms of target organ damage caused by hypertension: therapeutic potential. Pharmacol Ther 2006;111:81-98. (Pubitemid 43765539)
2. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA. Microcirculation in hypertension: a new target for treatment? Circulation 2001;104:735-40. (Pubitemid 32738532)
3. Mourad JJ, Laville M. Is hypertension a tissue perfusion disorder? Implications for renal and myocardial perfusion. J Hypertens Suppl 2006;24:S10-6. (Pubitemid 44299476)
4. Battegay EJ, de Miguel LS, Petrimpol M, Humar R. Effects of antihypertensive drugs on vessel rarefaction. Curr Opin Pharmacol 2007;7:151-7. (Pubitemid 46404741)
5. Redon J. Antihypertensive treatment: should it be titrated to blood pressure reduction or to target organ damage regression? Curr Opin Nephrol Hypertens 2005;14:448-52. (Pubitemid 41152707)
6. Lee JS, Song SH, Kim JM, et al. Angiopoietin-1 prevents hypertension and target organ damage through its interaction with endothelial Tie2 receptor. Cardiovasc Res 2008;78:572-80.
7. Olzinski AR, McCafferty TA, Zhao SQ, et al. Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection. Cardiovasc Res 2005;66:170-8. (Pubitemid 40357880)
8. Nakamura Y, Ono H, Zhou X, Frohlich ED. Angiotensin type I receptor antagonism and ACE inhibition produce similar renoprotection in N(omega)-nitro-L>-arginine methyl ester/spontaneously hypertensive rats. Hypertension 2001;37:1262-7. (Pubitemid 34163579)
9. Kubis N, Besnard S, Silvestre JS, et al. Decreased arteriolar density in endothelial nitric oxide synthase knockout mice is due to hypertension, not to the constitutive defect in endothelial nitric oxide synthase enzyme. J Hypertens 2002;20:273-80. (Pubitemid 34913792)
10. Kubis N, Richer C, Domergue V, Giudicelli JF, Lévy BI. Role of microvascular rarefaction in the increased arterial pressure in mice lacking for the endothelial nitric oxide synthase gene (eNOS3pt-/-). J Hypertens 2002;20:1581-7. (Pubitemid 34921182)
11. Kim W, Moon SO, Lee SY, et al. COMP-angiopoietin-1 ameliorates renal fibrosis in a unilateral ureteral obstruction model. J Am Soc Nephrol 2006;17:2474-83. (Pubitemid 44300963)
12. Cho CH, Kammerer RA, Lee HJ, et al. Designed angiopoietin-1 variant, COMP-Ang1, protects against radiation-induced endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004;101:5553-8. (Pubitemid 38481195)
13. Cho CH, Sung HK, Kim KT, et al. COMP-angiopoietin-1 promotes wound healing through enhanced angiogenesis, lymphangiogenesis, and blood flow in a diabetic mouse model. Proc Natl Acad Sci U S A 2006;103:4946-51.
14. Kobori H, Ozawa Y, Suzaki YY, Nishiyama A. Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol 2005;16:2073-80. (Pubitemid 41716438)
15. Du WM, Miao CY, Liu JG, Shen FM, Yang XQ, Su DF. Effects of long-term treatment with ketanserin on blood pressure variability and end-organ damage in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2003;41:233-9.
16. Noon JP, Walker BR, Webb DJ, et al. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest 1997;99:1873-9. (Pubitemid 27175934)
17. Antonios TF, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Rarefaction of skin capillaries in borderline essential hypertension suggests an early structural abnormality. Hypertension 1999;34:655-8. (Pubitemid 29496449)
18. Antonios TF, Rattray FM, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Rarefaction of skin capillaries in normotensive offspring of individuals with essential hypertension. Heart 2003;89:175-8. (Pubitemid 36115101)
19. Jung AD, Kim W, Park SH, et al. The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension. Korean Circ J 2009;39:180-4.